Preclinical combination strategies to enhance the efficacy of the anti-PD-1 antibody pembrolizumab

被引：0
|
作者：
Pinheiro, Elaine M.
Hinton, Marlene
Mangadu, Ruban
Cai, Mingmei
Phan, Uyen
Nebozhyn, Michael
Hirsch, Heather
Loboda, Andrey
Javaid, Sarah
Wang, Yaolin
Sriram, Venkataraman
Phillips, Joseph H.
McClanahan, Tern
Long, Brian
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-543
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
543
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Thiazolidinedione enhances the efficacy of anti-PD-1 monoclonal antibody in murine melanoma
    Zhang, Xinyi
    Gao, Yuan
    Tang, Keyun
    Li, Zongyu
    Halberstam, Alexandra A.
    Zhou, Liqun
    Perry, Rachel J.
    AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2024, 326 (03): : E341 - E350
  • [22] Anti-PD-1 antibody treatment for melanoma
    Ribas, Antoni
    Kirkwood, John M.
    Flaherty, Keith T.
    LANCET ONCOLOGY, 2018, 19 (05): : E219 - E219
  • [23] An unusual digestive complication under anti-PD-1 (pembrolizumab)
    Calvani, Julien
    Elia, Remie
    Battistella, Maxime
    Delyon, Julie
    Vivier-Chicoteau, Justine
    Gornet, Jean-Marc
    Lebbe, Celeste
    Baroudjian, Barouyr
    Bertheau, Philippe
    ANNALES DE PATHOLOGIE, 2020, 40 (04) : 320 - 323
  • [24] Early signs of efficacy in patients with anti-PD-1 naive and anti-PD-1 resistant HNSCC treated with NBTXR3/SBRT in combination with nivolumab or pembrolizumab in the phase I trial Study 1100
    Shen, Colette
    Frakes, Jessica M.
    Hackman, Trevor G.
    Niu, Jiaxin
    Weiss, Jared
    Caudell, Jimmy J.
    Yang, George Q.
    Seiwert, Tanguy Y.
    Murgu, Septimiu
    Kirtane, Kedar
    Rolando, David
    Tyan, Pavel
    Laterrot, Yasmine
    Gooi, Zhen
    Juloori, Aditya
    Rosenberg, Ari Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [25] Tumor treating fields (TTFields) elicit an anti-tumor immune response and in combination enhance anti-PD-1 treatment efficacy
    Kaynan, Noa
    Voloshin, Tali
    Davidi, Shiri
    Porat, Yaara
    Shteingauz, Anna
    Munster, Mijal
    Schneiderman, Rosa
    Giladi, Moshe
    Weinberg, Uri
    Palti, Yoram
    CANCER RESEARCH, 2020, 80 (16)
  • [26] Prospects of the potential strategies to improve the efficacy of anti-PD-1/PD-L1 therapy
    Yamaguchi, Hirohito
    Wang, Shao-Chun
    Hung, Mien-Chie
    CLINICAL AND TRANSLATIONAL MEDICINE, 2022, 12 (05):
  • [27] Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
    Hiro Sato
    Noriyuki Okonogi
    Takashi Nakano
    International Journal of Clinical Oncology, 2020, 25 : 801 - 809
  • [28] Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
    Sato, Hiro
    Okonogi, Noriyuki
    Nakano, Takashi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (05) : 801 - 809
  • [29] The molecular binding mechanism of tislelizumab, an investigational anti-PD-1 antibody, is differentiated from pembrolizumab and nivolumab
    Feng, Yingcai
    Hong, Yuan
    Sun, Hanzi
    Zhang, Bo
    Wu, Hongfu
    Li, Kang
    Liu, Xuesong
    Liu, Ye
    CANCER RESEARCH, 2019, 79 (13)
  • [30] Biophysical and Immunological Characterization and In Vivo Pharmacokinetics and Toxicology in Nonhuman Primates of the Anti-PD-1 Antibody Pembrolizumab
    Hutchins, Beth
    Starling, Gary C.
    McCoy, Mark A.
    Herzyk, Danuta
    Poulet, Frederique M.
    Dulos, John
    Liu, Liming
    Kang, Soonmo Peter
    Fayadat-Dilman, Laurence
    Hsieh, Mark
    Andrews, Christine L.
    Ayanoglu, Gulesi
    Cullen, Constance
    Malefyt, Rene de Waal
    Kastelein, Robert A.
    Le Saux, Sabine
    Lee, Julie
    Li, Sophie
    Malashock, Dan
    Sadekova, Svetlana
    Soder, George
    van Eenennaam, Hans
    Willingham, Aarron
    Yu, Ying
    Streuli, Michel
    Carven, Gregory J.
    van Elsas, Andrea
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (06) : 1298 - 1307
12345